Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression

(2013) M. Katout et al.   AMERICAN JOURNAL OF HYPERTENSION

Evaluation of inconsistency in networks of interventions

(2013) A. A. Veroniki et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults

(2012) Maria Tzefos et al.   ANNALS OF PHARMACOTHERAPY

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

(2012) K. Niswender et al.   DIABETES OBESITY & METABOLISM

GLP-1 based therapies: differential effects on fasting and postprandial glucose

(2012) M.S. Fineman et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Glucagon-like peptide-1 receptor agonists and their effects on weight reduction

(2012) Shyi-Jang Shin   Journal of Diabetes Investigation

Automating network meta-analysis

(2012) Gert van Valkenhoef et al.   Research Synthesis Methods

Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

(2011) B. Vergès et al.   DIABETES & METABOLISM

Achieving a clinically relevant composite outcome of an HbA1c of

(2011) B. Zinman et al.   DIABETES OBESITY & METABOLISM

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

(2011) Scott E. Kanoski et al.   NEUROPHARMACOLOGY

Errata

(2010)   DIABETES CARE

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

(2010) Deepson S Shyangdan et al.   BMC Endocrine Disorders

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE